最新ニュース Biodesix (NASDAQ:BDSX) 株価情報

Biodesix

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Biodesix Inc

News

Management

EOSE

Eos Energy Appoints Nathan Kroeker As COO And Eric Javidi As CFO

<a href="https://www.globenewswire.com/Tracker?data=XxXj3sBXAlFhxhyGKofSeOEgnBz3p9H8P81dxQL9GBWuQrWYg5JdbeH6R3eHgh-1LYRzz3-AUpa_w01D1fzIouuYTlDkwQ58RZk2tsz52xlodpFMKa_PM1VWNG2G64VxplaIyt4iGA9h1LMPVjCL9PjO_eDLSFPQs6yDEaf_B3Iw-q2ESYrw-fzuViULdpmk55-iOLExGVNbZeyq_NDnW6k-NPPzMCRtTF1inRZozbjXRKUnrepO6j4WXJCVfmepNsxSfU5ARVa7dYkuKAX-rpYbcQEKVSWFhYCqz2rwPPXjmdkiNI6-fZmzTpjGPLuyp1UMdlKnR6oXw1P0QUsZP4K4C87A4ggEAtcVknepr_TZlszOT7a9iuB0r-qZhkN4lkmpUd6bTGQ-ySgE3y-YgUwXm5db89iw_r7qUyTDj9veT_qhmkYAhhfH-6QBdfNg9sAOmFVUGNC92TtPrzL-Bp0qmksO2qsXWYqlxB1Mc2mCq1J9ndrgShutLRlO7CjZ1NQ66gsK-I3eVvIM6NvS8GawdJlouuXEXzz84_7zrfLk7bb5KoQS43lmTwIZ_xsaLVKEU8OGJ5jyVeuShET-u6GKVKmDXaPsdZB6SHRClr3x7Ko8sGYqLhXnzzfR3YxaG3EdG-_JZG2Wp0hPi-URW9aZ8RpPEAC_da2Au4oBGtEYKKFkSaM-qAHBD9cNjIyQs_0KZkmzyth_kfQKKTUVbNZEr9FB7u2D7LenVUjGyRq9rKjqRwbWjoWx22la1RGdNWxv21vpd8NLpOvoJTDc6xU7ODVO6CobCzY3yKe3pG8=">Crown Electrokinetics Corp.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) ("Crown" or the "Company"), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today announced that it has received a delisting determination from The Nasdaq Stock Market. The Company intends to submit a request for reconsideration to the Nasdaq Hearings Panel and to otherwise appeal the determination to the Nasdaq Listing and Hearing Review Council as necessary. While Crown pursues those processes, trading in the Company's common stock will be suspended on Nasdaq effective with the open of the market on Wednesday, March 5, 2025. The Company's common stock should be eligible to trade on the OTC Market's Pink Current Information tier effective with the open of the market on March 5, 2024.
Crown today is a fundamentally stronger company than in the past, with expanded business operations, growing revenue, and a strengthened financial position. The Company provides cutting-edge critical infrastructure solutions through its Crown Construction business, specializing in fiber optics, water service lines, water intake solutions, and XXL diameter pipelines. The Company has also significantly improved its financial standing, maintaining a cash balance exceeding $20 million with no debt. Since completing its reverse stock split, Crown has evidenced compliance with Nasdaq's minimum $1.00 bid price requirement for 22 consecutive business days, closing at approximately $3.40 per share on Monday, March 3, 2025. The Company otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market, including a significant margin of compliance above the minimum $2.5 million stockholders' equity requirement.

CRKN

Crown Receives Nasdaq Delisting Determination; Plans To Request Reconsideration

Contracts

Eos Energy Secures $8M Standalone BESS Order For Naval Base Of San Diego

comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) reported quarterly sales of $94.90 million which beat the analyst consensus estimate of $91.66 million by 3.54 percent. This is a 0.21 percent decrease over sales of $95.10 million the same period last year.

Earnings

Earnings Beats

SCOR

comScore Q4 Sales $94.90M Beat $91.66M Estimate

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.65 by 8.48 percent. This is a 1.65 percent decrease over earnings of $1.82 per share from the same period last year. The company reported quarterly sales of $5.91 billion which missed the analyst consensus estimate of $5.96 billion by 0.74 percent. This is a 1.84 percent decrease over sales of $6.02 billion the same period last year.

Earnings Misses

ROST

Ross Stores Q4 2024 GAAP EPS $1.79 Beats $1.65 Estimate, Sales $5.91B Miss $5.96B Estimate

National Research Appoints Trent Green As CEO

5 analysts have shared their evaluations of Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $11.4, a high estimate of $12.00, and a low estimate of $11.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1741122081_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Genius Sports by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Eric Ross</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Genius Sports. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Genius Sports compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Genius Sports's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Genius Sports's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GENI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Genius Sports analyst ratings.</a>
<h2>Get to Know Genius Sports Better</h2>
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
<h3>Financial Insights: Genius Sports</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Genius Sports's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.16% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.4%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Genius Sports's ROA excels beyond industry benchmarks, reaching 1.74%. This signifies efficient management of assets and strong financial health.
Debt Management: Genius Sports's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GENI

What 5 Analyst Ratings Have To Say About Genius Sports

7 analysts have shared their evaluations of Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $45.0, a high estimate of $75.00, and a low estimate of $4.00. A 23.51% drop is evident in the current average compared to the previous average price target of $58.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1741122073_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Silence Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Silence Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Silence Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Silence Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Silence Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SLN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Silence Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Silence Therapeutics: A Closer Look</h2>
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
<h3>Silence Therapeutics's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Silence Therapeutics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1491.89%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Silence Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 58.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Silence Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Silence Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.6%, the company showcases efficient use of assets and strong financial health.
Debt Management: Silence Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)

ARB IOT Group Limited ("ARB IOT" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) today announced that it has, through its indirect wholly owned subsidiary, ARB IOT Group Sdn Bhd, signed an artificial intelligence (AI) Products Supply Agreement with Gajah Kapitalan Sdn Bhd ("GKSB"), an entity dedicated to empowering Malaysian businesses through technological innovation, with a focus on delivering advanced computing systems for enterprises, research institutions and developers in Malaysia. This agreement paves the way for ARB IOT to supply 500 units of state-of-the-art ARB-222 AI servers ("AI Products") to provide high-performance immersible computer servers to GKSB in a deal valued at approximately US$45.0 million.
This milestone highlights ARB IOT's commitment to expanding its presence in the rapidly growing data center sector. By tapping into the rising demand for digital assets and leveraging its expertise in AI server solutions, the Company is strategically positioned to seize new opportunities driven by the latest advancements in AI, fostering sustainable growth and value creation for its stakeholders.

ARBB

ARB IOT Group Secures Order Worth ~$45M For AI Data Centre Server Solution

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated PVH and provided 12-month price targets. The average target is $113.33, accompanied by a high estimate of $144.00 and a low estimate of $95.00. Observing a downward trend, the current average is 10.13% lower than the prior average price target of $126.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1741122058_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of PVH by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Kimberly Greenberger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$144.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PVH. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PVH compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of PVH's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PVH's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PVH analyst ratings.</a>
<h2>Unveiling the Story Behind PVH</h2>
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites and about 1,500 stores, licenses its brands to third parties, and distributes its merchandise through department stores and other wholesale accounts. The firm traces its history to 1881 and is based in New York City.
<h3>Breaking Down PVH's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining PVH's financials over 3 months reveals challenges. As of 31 October, 2024, the company experienced a decline of approximately -4.56% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.85%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): PVH's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.52%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): PVH's ROA stands out, surpassing industry averages. With an impressive ROA of 1.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: PVH's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: PVH In The Eyes Of 9 Experts

In the last three months, 7 analysts have published ratings on NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for NNN REIT, presenting an average target of $45.0, a high estimate of $48.00, and a low estimate of $42.00. A decline of 2.98% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741122049_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of NNN REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>John Massocca</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$46.50</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NNN REIT. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NNN REIT compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NNN REIT's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into NNN REIT's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NNN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NNN REIT analyst ratings.</a>
<h2>Unveiling the Story Behind NNN REIT</h2>
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue. The maximum of the company's properties are located in the South and Southeast of the United States.
<h3>Breaking Down NNN REIT's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: NNN REIT's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 1.04%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: NNN REIT's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 44.73% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): NNN REIT's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): NNN REIT's ROA stands out, surpassing industry averages. With an impressive ROA of 1.1%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.0.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: NNN REIT In The Eyes Of 7 Experts

The White House Crypto Summit scheduled for March 7 will host a select group <a href="https://www.benzinga.com/crypto">of 20-25 industry leaders</a> in a roundtable setting, according to Fox Business journalist Eleanor Terrett.
As of March 4, official invitations for the event had yet to be distributed, reflecting a planning process still in flux.
The intimate gathering will include prominent figures from the cryptocurrency sector alongside key members of the Presidential Working Group on Digital Assets, signaling a focused discussion on the future of digital finance in the U.S.
Terrett <a href="https://x.com/EleanorTerrett/status/1896966911721607536">reported </a>that the guest list, smaller than initially expected, will feature notable industry figures such as Michael Saylor, alongside government officials like Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick, and Attorney General Pam Bondi.
"The gathering of around 20-25 people will be a roundtable setting at the White House," Terrett wrote in her scoop on X, emphasizing the event's exclusive nature. 
The summit, led by David Sacks and overseen by Bo Hines, executive director of President Donald Trump's digital asset task force, aims to address critical policy decisions for the crypto industry.
The event's structure has drawn attention amid broader speculation about potential regulatory changes, including a zero crypto tax policy proposed by Eric Trump. 
However, experts like Adam Cochran, founder of Cinneamhain Ventures, have cautioned that such a policy faces significant hurdles. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44120900/donald-trumps-bitcoin-xrp-cardano-reserve-proposal-drives-wedge-in-crypto-industry">Donald Trump&#8217;s Bitcoin, XRP, Cardano Reserve Proposal Drives Wedge In Crypto Industry</a>
"Even if the president announced it or signed an executive order, it wouldn't automatically become law," Cochran stated on X, underscoring that tax law changes require Congressional approval under the U.S. Constitution.
While the roundtable will focus on a select group, a larger, invite-only reception is planned afterward across the street from the White House for those who cannot attend the main discussion.
"This is all happening in real time with plans not 100% finalized so things could change," Terrett noted, highlighting the fluid nature of the summit's preparations. 
The event marks President Trump's first major engagement with the crypto community since taking office, reflecting his vocal support for positioning the U.S. as a global leader in digital assets.
The summit comes as debate intensifies over crypto tax reform, with investors and policymakers weighing the implications of eliminating capital gains taxes on cryptocurrencies. 
Attendees will include prominent project founders, CEOs of major crypto firms, investors, and regulators, according to an official statement from the Office of Communications. 
While the agenda remains under wraps, the roundtable format suggests a collaborative approach to tackling these complex issues.
Read Next:<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44117695/raoul-pal-predicts-extended-crypto-cycle-into-2026-bitcoin-solana-corrections-are-typical-volatility"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44117695/raoul-pal-predicts-extended-crypto-cycle-into-2026-bitcoin-solana-corrections-are-typical-volatility">Raoul Pal Predicts Extended Crypto Cycle Into 2026, Bitcoin, Solana Corrections Are Typical Volatility</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

White House Crypto Summit To Feature Roundtable With Industry Leaders Including Michael Saylor

During the last three months, 4 analysts shared their evaluations of Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Kimbell Royalty Partners, presenting an average target of $18.75, a high estimate of $23.00, and a low estimate of $14.00. A decline of 3.85% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741122036_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Kimbell Royalty Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kimbell Royalty Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kimbell Royalty Partners compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Kimbell Royalty Partners's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KRP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kimbell Royalty Partners analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Kimbell Royalty Partners's Background</h2>
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
<h3>Kimbell Royalty Partners's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Kimbell Royalty Partners's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -16.16% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -53.33%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Kimbell Royalty Partners's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Kimbell Royalty Partners In The Eyes Of 4 Experts

7 analysts have shared their evaluations of BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $28.71, a high estimate of $33.00, and a low estimate of $25.00. This upward trend is apparent, with the current average reflecting a 9.83% increase from the previous average price target of $26.14.
<img src="https://www.benzinga.com/files/images/story/2025/1741122020_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive BKV. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BKV. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BKV compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of BKV's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into BKV's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BKV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BKV analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into BKV's Background</h2>
BKV Corp is a growth-driven energy company. Its core business is to produce natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).
<h3>Breaking Down BKV's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining BKV's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 26.48% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -32.97%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): BKV's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.64%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): BKV's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.55%, the company may face hurdles in achieving optimal financial performance.
Debt Management: BKV's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down BKV: 7 Analysts Share Their Views

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.62% on an annualized basis producing an average annual return of 31.01%. Currently, Ascendis Pharma has a market capitalization of $9.09 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741122010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ASND

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

<a href="https://register.epo.org/application?number=EP19190373" title="https://register.epo.org/application?number=EP19190373">https://register.epo.org/application?number=EP19190373</a>

Biotech

General

HSDT

Helius Medical Has Received A Decision To Grant European Patent Number EP3632505 Titled "NON-INVASIVE NEUROMODULATION (TO TREAT VARIOUS MALADIES SUCH AS TRAUMATIC BRAIN INJURY, STROKE, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE)"

WIIM

New Fortress Energy shares are trading higher after the company reported better-than-expected Q4 financial results.

CMTL

Comtech shares are trading higher after the company announced a $40 million capital infusion. .

ASTS

AST SpaceMobile shares are trading higher. The company reported Q4 financial results.

GTLB

GitLab shares are trading higher after the company reported better-than-expected Q4 financial results.

Press Releases

Biodesix to Present at Two Investor Conferences in September

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Biodesix to Participate in Three Investor Conferences in November

Biodesix Announces Third Quarter 2024 Results and Highlights

Health Care

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

BDSX

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

Biodesix

ニュース

最新ニュース Biodesix (NASDAQ:BDSX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル